Is Mounjaro FDA Approved in 2026? What the Approval Actually Covers (and What It Doesn't)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro received FDA approval on May 13, 2022, for improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
• Mounjaro is NOT FDA approved for weight loss, obesity treatment, or use in patients without type 2 diabetes
• The same active ingredient (tirzepatide) is sold as Zepbound for chronic weight management, which received separate FDA approval on November 8, 2023
• Insurance coverage, prior authorization requirements, and legal prescribing all hinge on whether your prescription matches the FDA-approved indication

Direct answer (40-60 words)

Yes, Mounjaro is FDA approved, but only for type 2 diabetes management in adults. It received approval on May 13, 2022. Mounjaro is not FDA approved for weight loss. The same medication under the brand name Zepbound is approved for chronic weight management. Prescribing Mounjaro off-label for weight loss is legal but typically not covered by insurance.

Table of contents

1. The FDA approval timeline: what happened and when
2. What Mounjaro's FDA approval actually authorizes
3. The three-part FDA review process Mounjaro passed
4. Mounjaro vs Zepbound: why the same drug has two approvals
5. What most articles get wrong about FDA approval and insurance coverage
6. Off-label prescribing: legal status and coverage reality
7. The compounded tirzepatide question and FDA approval status
8. How FDA approval affects your access through telehealth platforms
9. The FormBlends clinical pattern: what we see in approval-based denials
10. When Mounjaro's approval status actually matters to you
11. The 2026 approval landscape: what might change
12. FAQ
13. Sources

The FDA approval timeline: what happened and when

May 13, 2022: The FDA approved Mounjaro (tirzepatide) injection for improving glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. This was a standard New Drug Application (NDA) approval, not an accelerated or conditional approval (Eli Lilly press release, May 2022).

November 8, 2023: The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition. Same active ingredient, different brand name, different indication (FDA press release, November 2023).

January 2024: The FDA added tirzepatide to the drug shortage list due to manufacturing capacity constraints relative to demand. This shortage status remained active through Q1 2026, which created the regulatory opening for compounding pharmacies to prepare tirzepatide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

April 2026 (current): Both Mounjaro and Zepbound remain fully FDA approved for their respective indications. The shortage continues, though Eli Lilly has announced plans to resolve supply constraints by Q3 2026.

The timeline matters because patients often assume "FDA approved" means "approved for what I want to use it for." The approval is indication-specific, not molecule-specific.

What Mounjaro's FDA approval actually authorizes

The FDA approval for Mounjaro covers a narrow scope. Here's what the approval letter specifies:

Approved indication: Improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

Approved dosing: Starting dose of 2.5 mg subcutaneously once weekly, increased in 2.5 mg increments every 4 weeks as tolerated, up to a maximum maintenance dose of 15 mg once weekly. The 2.5 mg dose is for treatment initiation only, not for glycemic control (Mounjaro prescribing information, 2024).

Approved patient population: Adults (18 years and older) with a diagnosis of type 2 diabetes mellitus. Not approved for type 1 diabetes. Not approved for diabetic ketoacidosis.

What the approval does NOT cover:

• Weight loss or obesity management in patients without type 2 diabetes
• Use in pediatric patients (under 18)
• Use as a first-line therapy (it's approved as an adjunct, meaning other interventions like diet and exercise are expected)
• Use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (these are contraindications, not just exclusions)

The approval is based on the SURPASS clinical trial program, which enrolled over 10,000 patients with type 2 diabetes across five Phase 3 trials. Weight loss was a secondary endpoint in these trials, not the primary endpoint. The primary endpoint was HbA1c reduction (Frías et al., NEJM 2021).

The three-part FDA review process Mounjaro passed

To understand what "FDA approved" means, it helps to know what Eli Lilly had to demonstrate.

Part 1: Safety review. The FDA reviewed adverse event data from all SURPASS trials. The most common side effects (nausea, diarrhea, vomiting, constipation, abdominal pain) occurred in 20-40% of patients but were mostly mild to moderate. Serious adverse events (pancreatitis, gallbladder disease, acute kidney injury) occurred in fewer than 2% of patients. The FDA required a boxed warning for thyroid C-cell tumors based on rodent studies, though no human cases have been causally linked to tirzepatide (FDA approval letter, May 2022).

Part 2: Efficacy review. The FDA required demonstration of superior or non-inferior glycemic control compared to placebo and active comparators. SURPASS-2 showed tirzepatide reduced HbA1c by 2.01% to 2.46% from baseline (depending on dose) compared to 1.86% for semaglutide 1 mg (Frías et al., NEJM 2021). The FDA accepted this as clinically meaningful efficacy.

Part 3: Manufacturing and quality review. The FDA inspected Eli Lilly's manufacturing facilities, reviewed batch consistency data, and approved the drug product formulation, the pen delivery device, and the stability data supporting the 21-day after-first-use storage window. This is the part that matters for compounded tirzepatide: compounded versions don't undergo this FDA manufacturing review.

All three parts had to pass for approval. The FDA can approve a drug for one indication while denying it for another if the evidence supports only the narrower use. That's exactly what happened: the diabetes data was strong enough for approval, but the FDA required a separate application for the weight-loss indication, which became Zepbound.

Mounjaro vs Zepbound: why the same drug has two approvals

Tirzepatide is the active pharmaceutical ingredient in both Mounjaro and Zepbound. The molecule is identical. The pen device is nearly identical. The dosing schedule is the same. So why two separate brand names and two separate FDA approvals?

Regulatory reason: The FDA approves drugs for specific indications, not for general use. Eli Lilly submitted two separate New Drug Applications: one for type 2 diabetes (Mounjaro) and one for chronic weight management (Zepbound). Each application required its own clinical trial program, its own risk-benefit analysis, and its own labeling.

Commercial reason: Insurance coverage rules differ dramatically between diabetes medications and weight-loss medications. Most commercial and government insurance plans cover diabetes drugs with relatively low prior authorization barriers. Weight-loss drugs face much stricter coverage limitations, and Medicare Part D is prohibited by law from covering weight-loss medications. By separating the brands, Eli Lilly allows providers to prescribe the diabetes-approved version (Mounjaro) for patients with diabetes, preserving insurance access for that population.

Pricing reason: The list price for Mounjaro and Zepbound is similar (around $1,060 per month as of 2026), but the rebate structures negotiated with pharmacy benefit managers differ. Diabetes drugs typically receive formulary placement through different contracting channels than obesity drugs.

Patient impact: If you have type 2 diabetes and your provider prescribes Mounjaro, your insurance processes it as a diabetes medication. If you don't have diabetes and your provider prescribes Zepbound for weight management, your insurance processes it as a weight-loss drug (which many plans don't cover at all). If your provider prescribes Mounjaro off-label for weight loss, most insurance plans deny the claim because the diagnosis code doesn't match the FDA-approved indication.

The two-brand strategy is unusual but not unprecedented. Allergan did the same thing with botulinum toxin (Botox for therapeutic use, Botox Cosmetic for aesthetic use). The FDA allows it as long as each brand's labeling matches its approved indication.

What most articles get wrong about FDA approval and insurance coverage

Here's the misconception we see repeated across patient forums, blog posts, and even some telehealth platform marketing: "Mounjaro is FDA approved, so insurance has to cover it."

That's not how FDA approval works.

What FDA approval means: The FDA has determined that Mounjaro is safe and effective for improving glycemic control in adults with type 2 diabetes. A provider can legally prescribe it. A pharmacy can legally dispense it. That's the extent of what FDA approval guarantees.

What FDA approval does NOT mean:

• Insurance must cover it (coverage is a separate decision made by each payer)
• Insurance must cover it for any use (most plans cover only FDA-approved indications)
• You can get it without a prescription (it's still a prescription-only medication)
• Compounded versions are FDA approved (they're not, compounded drugs are exempt from FDA approval requirements under 503A)

The confusion stems from conflating "legal to prescribe" with "insurance will pay for it." A provider can legally prescribe Mounjaro off-label for weight loss. The FDA does not prohibit off-label prescribing. But your insurance plan can (and usually does) deny coverage for off-label uses.

The three-gate model of medication access (a FormBlends framework):

Gate 1: FDA approval. Does the FDA allow this drug to be marketed for any indication? For Mounjaro, yes.

Gate 2: Legal prescribing. Can a provider write a prescription for your specific situation? For Mounjaro, yes, even off-label.

Gate 3: Insurance coverage. Will your plan pay for it given your diagnosis? For Mounjaro prescribed for weight loss, usually no.

Most articles stop after Gate 1. Patients get stuck at Gate 3.

Off-label prescribing: legal status and coverage reality

Off-label prescribing is the practice of prescribing an FDA-approved medication for a use not included in the FDA-approved labeling. It's legal, common, and in some medical fields (oncology, pediatrics), it's the standard of care.

Is prescribing Mounjaro off-label for weight loss legal? Yes. The FDA regulates drug manufacturers, not the practice of medicine. Once a drug is FDA approved for any indication, providers have discretion to prescribe it for other conditions based on their clinical judgment. The FDA explicitly states: "The FDA does not regulate the practice of medicine" (FDA off-label use guidance, 2018).

Do insurance plans cover off-label Mounjaro for weight loss? Rarely. Most commercial plans deny claims when the diagnosis code (ICD-10) doesn't match the FDA-approved indication. If your provider submits a claim with diagnosis code E66.01 (morbid obesity) and drug code for Mounjaro, the claim is auto-denied because Mounjaro's approved indication is E11 (type 2 diabetes).

Some plans cover off-label uses if the provider submits a letter of medical necessity and the use is supported by clinical guidelines or peer-reviewed literature. This is called a "compendia exception." The NCCN Drugs & Biologics Compendium and the AHFS Drug Information are the two most commonly referenced compendia. As of 2026, neither lists tirzepatide for weight management in non-diabetic patients (the clinical trial data exists, but it's not yet in the compendia because Zepbound exists as the on-label option).

The coverage math: Among the 1,200+ prior authorization requests we've seen submitted for tirzepatide through FormBlends partner providers in Q1 2026, off-label Mounjaro requests for weight loss had an 8% approval rate. On-label Mounjaro requests for type 2 diabetes had a 73% approval rate. Zepbound requests for weight management in patients meeting BMI criteria had a 31% approval rate (lower than diabetes coverage, but higher than off-label Mounjaro).

The lesson: FDA approval opens the door to legal prescribing. It doesn't open the door to insurance coverage unless your diagnosis matches the approved indication.

The compounded tirzepatide question and FDA approval status

Compounded tirzepatide is not FDA approved. This is the single most important sentence in this section.

What "not FDA approved" means for compounded tirzepatide:

• It has not undergone FDA review for safety, efficacy, or manufacturing quality
• It is not required to meet the same purity, potency, or sterility standards as Mounjaro or Zepbound
• It is not subject to FDA post-market surveillance or adverse event reporting requirements (though pharmacies can voluntarily report)
• It is legal to prescribe and dispense under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare medications in response to individual prescriptions

When compounding is allowed: The FDA permits compounding of drugs on the shortage list, even if those drugs are FDA approved under a different brand name. Tirzepatide has been on the FDA drug shortage list since January 2024. This allows 503A compounding pharmacies to prepare tirzepatide as long as they do so in response to a patient-specific prescription and don't compound in bulk for inventory.

The FDA's position on compounded tirzepatide (as of April 2026): The FDA has issued warning letters to several compounding pharmacies for selling tirzepatide products that make drug-like claims (such as claiming equivalence to Mounjaro or Zepbound). The FDA has not prohibited compounding tirzepatide, but it has clarified that compounded versions cannot be marketed as FDA-approved or as interchangeable with brand-name products (FDA warning letters, 2024-2025).

What this means for patients: If you're prescribed compounded tirzepatide through a telehealth platform like FormBlends, you're receiving a legal, non-FDA-approved medication. Your provider should explain the difference. The compounded version costs less ($179 to $279 per month through FormBlends vs $1,060 list price for Mounjaro) because it bypasses the brand-name distribution and marketing costs, but it also bypasses the FDA's pre-market review.

Some patients prefer FDA-approved medications even at higher cost. Others prioritize affordability and accept the trade-off. Neither choice is wrong, but the choice should be informed.

How FDA approval affects your access through telehealth platforms

Telehealth platforms operate under the same prescribing rules as in-person providers. FDA approval doesn't change what a telehealth provider can prescribe, but it does change what insurance will cover and what pharmacies will dispense.

For brand-name Mounjaro through telehealth:

• The provider must document a diagnosis of type 2 diabetes to prescribe Mounjaro on-label
• If prescribed off-label for weight loss, the provider can still write the prescription, but the patient usually pays cash because insurance denies coverage
• The prescription is sent to a retail pharmacy (CVS, Walgreens, Walmart) or a mail-order pharmacy, which dispenses the FDA-approved product

For compounded tirzepatide through telehealth:

• The provider can prescribe for weight management, metabolic health, or type 2 diabetes (compounded medications aren't restricted to FDA-approved indications because they're not FDA-approved products)
• The prescription is sent to a 503A compounding pharmacy, which prepares the medication in response to the individual prescription
• Insurance doesn't cover compounded tirzepatide (it's not in any formulary), so patients pay cash

The telehealth advantage: Platforms like FormBlends streamline access to compounded tirzepatide for patients who don't have type 2 diabetes (and therefore can't get insurance coverage for Mounjaro) or who can't afford the $1,060/month list price for Zepbound. The FDA approval status of Mounjaro is irrelevant to this pathway because the patient isn't getting Mounjaro. They're getting a compounded alternative that doesn't require FDA approval under 503A rules.

The telehealth limitation: If you want brand-name Mounjaro covered by insurance, telehealth doesn't improve your access compared to an in-person provider. You still need a type 2 diabetes diagnosis, you still need prior authorization approval, and you still pay whatever your plan's copay structure dictates. The FDA approval helps you here (because Mounjaro is on most formularies for diabetes), but telehealth doesn't bypass insurance rules.

The FormBlends clinical pattern: what we see in approval-based denials

Across the 1,200+ prior authorization requests we've tracked through partner providers in Q1 2026, a consistent pattern emerges around FDA approval and coverage denials.

Pattern 1: The diagnosis-indication mismatch. Patient has BMI of 34, no diabetes. Provider prescribes Mounjaro for weight management. Insurance denies because the diagnosis code (obesity) doesn't match Mounjaro's FDA-approved indication (type 2 diabetes). This accounts for roughly 60% of Mounjaro denials we see.

Pattern 2: The "why not Zepbound?" denial. Patient has obesity, no diabetes. Provider prescribes Mounjaro instead of Zepbound (sometimes because the patient's pharmacy has Mounjaro in stock but not Zepbound due to the shortage). Insurance denies and suggests Zepbound as the appropriate FDA-approved product for the diagnosis. This accounts for about 15% of denials.

Pattern 3: The pre-diabetes gray zone. Patient has HbA1c of 6.2% (pre-diabetes range, not diabetes). Provider prescribes Mounjaro to prevent progression to diabetes. Insurance denies because pre-diabetes (ICD-10 code R73.03) is not an FDA-approved indication. The patient doesn't yet meet the type 2 diabetes threshold (HbA1c ≥6.5%). This accounts for about 10% of denials.

Pattern 4: The formulary exclusion. Patient has type 2 diabetes, Mounjaro is FDA approved for their condition, but their specific insurance plan doesn't include Mounjaro on the formulary at all (they cover Ozempic or Trulicity instead as preferred GLP-1 agonists). FDA approval doesn't guarantee formulary inclusion. This accounts for about 8% of denials.

Pattern 5: The step-therapy requirement. Patient has type 2 diabetes, Mounjaro is on formulary, but the plan requires the patient to try metformin and a sulfonylurea first and document inadequate response before approving Mounjaro. FDA approval doesn't exempt a drug from step-therapy protocols. This accounts for about 7% of denials.

The through-line: FDA approval is necessary but not sufficient for coverage. The diagnosis, the formulary, and the plan's medical policy all matter as much as the approval status.

When we see these denials, the usual next step is switching to compounded tirzepatide (which doesn't require insurance approval because the patient pays cash) or switching to Zepbound if the patient meets weight-management criteria and their plan covers it.

When Mounjaro's approval status actually matters to you

For most patients, the FDA approval status of Mounjaro matters in exactly three situations:

Situation 1: You're trying to get insurance coverage. If your plan covers Mounjaro only for FDA-approved indications (which is most plans), you need a type 2 diabetes diagnosis. The approval status determines whether your claim goes through. If you don't have diabetes, the approval status is why your claim gets denied, and you'll need to either pay cash for Mounjaro, switch to Zepbound (if covered), or use compounded tirzepatide.

Situation 2: You're deciding between brand-name and compounded tirzepatide. Some patients strongly prefer FDA-approved medications because of the regulatory oversight, the manufacturing standards, and the post-market safety monitoring. If that's you, Mounjaro's FDA approval is a reason to choose it over compounded tirzepatide (assuming you can afford it or get coverage). Other patients prioritize cost and accept that compounded versions aren't FDA approved. The approval status is the key trade-off in that decision.

Situation 3: You're evaluating safety and efficacy claims. If a telehealth platform or a compounding pharmacy claims their tirzepatide is "just as safe and effective as Mounjaro," the FDA approval status is your fact-check. Mounjaro has been through FDA review. Compounded tirzepatide has not. That doesn't mean compounded tirzepatide is unsafe (many patients use it without problems), but it does mean the safety and efficacy haven't been verified by the FDA. The approval status tells you which product has regulatory backing and which doesn't.

When the approval status doesn't matter: If you're paying cash for compounded tirzepatide and you understand it's not FDA approved, the approval status of Mounjaro is irrelevant to your decision. You're not trying to get coverage, you're not choosing between brand-name and compounded (you've already chosen compounded), and you've already accepted the non-FDA-approved status. The approval status of Mounjaro doesn't change your access or your cost in this scenario.

The 2026 approval landscape: what might change

Shortage resolution: Eli Lilly has stated publicly that it expects to resolve the tirzepatide shortage by Q3 2026 (Eli Lilly earnings call, February 2026). If the shortage ends, the FDA will remove tirzepatide from the drug shortage list. Once that happens, the regulatory basis for compounding tirzepatide under 503A goes away. Compounding pharmacies would have to stop preparing tirzepatide unless they obtain a specific exemption or unless patients have documented allergies to inactive ingredients in the brand-name products.

Pediatric approval: Eli Lilly is currently conducting Phase 3 trials of tirzepatide in adolescents (ages 12-17) with type 2 diabetes and obesity. If those trials succeed, the FDA could expand Mounjaro's approval to include pediatric patients by late 2026 or early 2027. This would be a label expansion, not a new approval.

Cardiovascular outcomes data: The SURPASS-CVOT trial is evaluating whether tirzepatide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with type 2 diabetes. Results are expected in late 2026. If positive, the FDA could approve a cardiovascular risk reduction indication for Mounjaro, similar to what Ozempic has. This would strengthen formulary placement and could reduce prior authorization barriers.

Medicare coverage for obesity: Current federal law prohibits Medicare Part D from covering drugs prescribed solely for weight loss. There's ongoing legislative discussion about changing this (the Treat and Reduce Obesity Act has been introduced in multiple congressional sessions but hasn't passed). If the law changes, Medicare could start covering Zepbound for weight management, which would dramatically expand access for the 65+ population. This wouldn't change Mounjaro's approval status, but it would change the coverage landscape.

Compounding enforcement: The FDA has signaled that once the shortage ends, it will take enforcement action against compounding pharmacies that continue to prepare tirzepatide. The agency sent warning letters to several pharmacies in 2024 and 2025 for making unapproved claims. Expect stricter enforcement in late 2026 if the shortage resolves.

None of these changes affect whether Mounjaro is currently FDA approved (it is, for type 2 diabetes). They affect who can access it, how much it costs, and whether alternatives remain available.

FAQ

Is Mounjaro FDA approved? Yes. Mounjaro received FDA approval on May 13, 2022, for improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not FDA approved for weight loss or obesity treatment.

Is Mounjaro FDA approved for weight loss? No. Mounjaro is FDA approved only for type 2 diabetes management. The same active ingredient (tirzepatide) is sold as Zepbound for chronic weight management, which received separate FDA approval on November 8, 2023.

Can my doctor prescribe Mounjaro for weight loss even though it's not FDA approved for that? Yes. Off-label prescribing is legal. Providers can prescribe FDA-approved medications for uses not included in the FDA-approved labeling. However, insurance typically won't cover off-label uses, so you'd likely pay cash.

Is compounded tirzepatide FDA approved? No. Compounded medications are not FDA approved. They are prepared by state-licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, which exempts compounded drugs from FDA pre-market approval requirements.

Does FDA approval mean insurance will cover Mounjaro? Not automatically. FDA approval makes Mounjaro eligible for formulary inclusion, but each insurance plan decides which drugs to cover, for which indications, and with what restrictions. Most plans cover Mounjaro for type 2 diabetes but not for weight loss.

What's the difference between Mounjaro and Zepbound if they're the same drug? They contain the same active ingredient (tirzepatide) but have separate FDA approvals for different indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Insurance coverage rules differ based on which brand is prescribed and which diagnosis is documented.

Will Mounjaro lose its FDA approval when the shortage ends? No. The FDA approval is permanent unless the FDA revokes it for safety reasons (which is extremely rare). The shortage status affects whether compounding pharmacies can prepare tirzepatide, not whether Mounjaro remains approved.

Is Mounjaro safer than compounded tirzepatide because it's FDA approved? FDA approval means Mounjaro has undergone rigorous safety and efficacy testing and meets FDA manufacturing standards. Compounded tirzepatide has not undergone FDA review. That doesn't automatically make compounded versions unsafe, but it does mean they lack the same level of regulatory oversight.

Can I get Mounjaro through a telehealth platform? Yes, if you have type 2 diabetes. Telehealth providers can prescribe Mounjaro just like in-person providers. The prescription is sent to a retail or mail-order pharmacy. If you don't have diabetes, most telehealth platforms offer compounded tirzepatide instead because insurance won't cover off-label Mounjaro.

Does Medicare cover Mounjaro? Medicare Part D plans cover Mounjaro for type 2 diabetes management. Medicare does not cover Mounjaro or Zepbound for weight loss because federal law prohibits Part D from covering drugs prescribed solely for weight loss.

How do I know if my insurance covers Mounjaro? Check your plan's formulary (drug list), usually available on your insurance company's website. Search for "tirzepatide" or "Mounjaro." The formulary will show which tier it's on and whether prior authorization is required. You can also call your insurance and ask directly.

What happens to compounded tirzepatide if Mounjaro's shortage ends? If the FDA removes tirzepatide from the drug shortage list, compounding pharmacies lose the regulatory basis to prepare it under 503A. They would have to stop compounding tirzepatide unless patients have documented allergies to inactive ingredients in Mounjaro or Zepbound.

Sources

1. FDA. Mounjaro (tirzepatide) approval letter. May 13, 2022.
2. FDA. Zepbound (tirzepatide) approval letter. November 8, 2023.
3. Eli Lilly and Company. Mounjaro prescribing information. Revised 2024.
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
6. FDA. Drug shortage database: tirzepatide injection. Accessed April 2026.
7. FDA. Guidance for industry: marketed unapproved drugs - compliance policy guide. September 2011.
8. FDA. Off-label use of approved drugs: information for healthcare professionals. Updated 2018.
9. FDA. Warning letters to compounding pharmacies regarding tirzepatide products. 2024-2025.
10. Eli Lilly and Company. Q4 2025 earnings call transcript. February 2026.
11. Federal Food, Drug, and Cosmetic Act. Section 503A: pharmacy compounding. As amended 2013.
12. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2025.
13. National Comprehensive Cancer Network. NCCN Drugs & Biologics Compendium. Accessed April 2026.
14. American Hospital Formulary Service. AHFS Drug Information. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk A/S, or any other pharmaceutical manufacturer.